Adore Settles With Nationwide Class Over Apple Stem Cell Anti-Aging Claims
This article was originally published in The Rose Sheet
The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.
You may also be interested in...
Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.
A proposed consent agreement between L’Oreal USA and the Federal Trade Commission bars the company from claiming that skin-care products from its Lancome and L’Oreal Paris brands target users’ genes to award anti-aging benefits. The settlement, which is subject to public comment and final FTC approval, follows a 2012 warning letter from FDA that cited some of the same marketing claims.